Syntermed’s Emory Toolbox™ 4.0 and Advances in Heart Failure Diagnosis

Share Article

This month, Syntermed, Inc. launched its new Emory Toolbox 4.0 software through all channels, OEMS, VARS and direct. Emory Toolbox 4.0 is currently the only system .NET architecture for evaluating two different avenues of heart failure and quantitatively providing a more accurate diagnosis of the disease.

Emory Cardiac Toolbox

Syntermed's Emory Toolbox 4.0 decision support software shows a slices screen shot for a myocardial perfusion SPECT study.

Now rebuilt on a .NET architecture, Emory Toolbox 4.0 has a higher level of expert decision support, resulting in what Syntermed calls “smart scores." -- Ken Van Train, President, Syntermed, Inc.

Syntermed, Inc., a medical imaging software company has introduced a new level of expert system interpretation to SPECT and PET cardiac studies. This month the Emory Toolbox™ 4.0 software became widely available to nuclear medicine labs.

“When you add our advanced cardiac tools, SyncTool™ for dyssynchrony and AdreView Tools™ for evaluating the sympathetic nerves in the heart, you get an optimum system for evaluating heart failure patients,” says Ken Van Train, President, Syntermed, Inc. “Emory Toolbox 4.0 is currently the only system on the market for evaluating two different avenues of heart failure and quantitatively providing a more accurate diagnosis of the disease.”

Throughout its history, Syntermed, Inc. has had a longstanding relationship with Emory University. The original intellectual property for Emory Cardiac Toolbox was developed by Emory nuclear cardiology researcher Ernest Garcia, PhD in 1998. In 2012, Syntermed, Inc. received an award (1 R42 HL106818-01) from the National Heart, Lung and Blood Institute titled, Novel WEB Decision Support System for cardiac image interpretation and reporting. “The result is Emory Toolbox 4.0, now the most comprehensive system for SPECT and PET quantitation,” adds Van Train. “Now rebuilt on a .NET architecture, Emory Toolbox 4.0 has a higher level of expert decision support, resulting in what we call “smart scores.” While the Toolbox has been widely used for many years, and previous versions of the software are operating in nuclear cardiology labs worldwide, the 4.0 version will still continue to provide the most extensive list of normal limit protocols unmatched by our competitors. In most cases our customers, whether they work with us directly or through their OEM imaging hardware representative or value added reseller, are typically seeking normal limits to match the protocol they are currently using. Emory Toolbox 4.0 has that flexibility.”

In the field, Emory Cardiac Toolbox 4.0 has begun to empower new workflow lab efficiencies. “Our development team worked closely with Ernest Garcia, PhD, and colleagues at Emory University and Larry Klein, MD, and the lab at the University of North Carolina to achieve a higher level of decision support,” said Christian Del’Aune, Director of Technology for Syntermed. “Toolbox 4.0 with its “smart scores” is like having a second nuclear medicine expert analyzing the data while the physician is doing his or her interpretation of the data; the decision support system provides a comprehensive interpretation incorporating every aspect of the patients study, i.e. gender, prone/supine, AC/nonAC, quality control, etc. resulting in an in-depth expert interpretation for consideration at record speeds and in natural language.”    

Company Information
Since 1999, Syntermed, Inc., a privately-held nuclear medicine imaging and informatics software company based in Atlanta, GA, has served nuclear cardiology and nuclear medicine labs through all major OEM imaging providers and leading value added resellers, as well as, direct. Syntermed software quantifies and delivers decision support for the analysis of SPECT or PET images of the heart and brain.

□ Emory Toolbox™, now in its fourth generation, is one of the most widely applied methods of cardiac imaging, used in labs worldwide. Version 4.0 is distinguished by “smart scores,” a proprietary algorithm. Additional advanced cardiac tools, SyncTool™ and AdreView Tools™ are expanding the capabilities of the nuclear cardiology lab.

□ Syntermed also has a line of software products that support the diagnosis of dementia. NeuroQ™, the industry’s leading solution for the quantification of brain studies with PET-FDG now includes support for florbetapir F18.

□ Syntermed’s expertise also benefits those physicians and nuclear medicine facilities that seek to customize their SPECT and PET cardiac studies with advanced quantification, applications and a comprehensive level of reporting, called SmartReport™. Syntermed Live™ is already being used by many nuclear medicine physicians to get round-the-clock secure, remote access to their studies and reports no matter where they are. These labs upgrading to Emory Toolbox 4.0 will automatically get the decision support system with “smart scores,” powered by Syntermed IDS. SmartReport™ is an optional reporting package designed to seamlessly support ASNC ImageGuide Registry, and can also be fully integrated with EMR at the hospital enterprise level.

□ All of Syntermed’s software is compatible with virtually any nuclear medicine workstation or PC/MAC that supports Microsoft® Windows® operating system.

Syntermed officers: Michael Lee, Chairman and CEO; Ken Van Train, President, and Christian Del'Aune, Director of Technology

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Roberts
since: 09/2012
Follow >
Follow us on
Visit website